Incorrect use of orlistat and sibutramine in clinical practice
- PMID: 17205321
- DOI: 10.1007/s00228-006-0226-8
Incorrect use of orlistat and sibutramine in clinical practice
Abstract
Objective: To investigate how the antiobesity drugs orlistat and sibutramin are prescribed in relation to the approved indications and the Swedish subsidiary rules.
Methods: Anonymous survey to prescribers of a random sample of 2000 out of 20,000 prescription of orlistat and sibutramin.
Results: The response rate was around 65%. About half of the patients were not treated in accordance with the approved indications and a fourth of the patients prescribed sibutramin had one or several contraindications to the drug. The subsidiary rules were not followed in the majority of cases.
Conclusion: Deviation from the approved indications and subsidiary criteria of orlistat and sibutramin is a question of waste of medical and economic resources. Prescribing of sibutramin to patients with contraindications is a serious health hazard.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
